Accustem Sciences Inc.
ACUT
We are a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people worldwide who are diagnosed with cancer each year. Our plan is to develop and commercialize a suite of novel genomic tests that support decision making along the entire continuum of oncology care.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$3M
▼ -16.7% YoY
Op. Margin
–
ROIC
-7751.96%
▼ -2875.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$842K
▼ -28.1% YoY
Op. Cash Flow (TTM)
-$842K
▼ -28.1% YoY
Net Debt
$27K
Cash & Equiv.
$15K
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ACUT
Accustem Sciences (ACUT) in two numbers
Questions about Accustem Sciences
Does Accustem Sciences (ACUT) pay a dividend?
No. Accustem Sciences (ACUT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 20 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 19 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ACUT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ACUT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.